DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
A phase 1/2 trial of DZD8586 in diffuse large b-cell lymphoma, run by Dizal Pharmaceuticals, now recruiting.
Overview
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) is a phase 1/2 interventional study registered as NCT07059650 by Dizal Pharmaceuticals, with 150 participants planned, started 2025-08-19 and due to reach its primary completion in 2030-10. Interventions recorded: DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
Setting
A Phase Ib/II, Multicenter Study to Evaluate the Efficacy and Safety of DZD8586 Combination Therapy in Diffuse Large B-cell Lymphoma
Phase
Phase 1/2
Sponsor
Dizal Pharmaceuticals
Registry
Enrolled
150
Similar pages
not linked directly; found by shared links- TrialDZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Shares DZD8586, Dizal Pharmaceutical.
- TrialA Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Shares DZD8586, Dizal Pharmaceutical.
- TrialA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Shares DZD8586, Dizal Pharmaceutical.